Outpatient Rhythm Monitoring After TAVR Could Save Us from Some Pacemakers?

Delayed high-grade block after transcatheter aortic valve replacement (TAVR) goes unnoticed in patients undergoing TAVR without prior conduction disorders because, most times, it takes place during hospitalization or immediately after the procedure.

tavi vs cirugia partner i

Right bundle branch block is a risk factor, but it has poor sensitivity for the prediction of high-grade blocks, and there may be other risk factors currently unclear.

Outpatient monitoring may identify it quickly, allowing us to be expeditious regarding the implantation of a permanent pacemaker in about 10% of patients after TAVR. Further studies are obviously necessary to clarify the incidence and risk factors for proper selection of patients warranting outpatient monitoring.

This work included 150 consecutive patients who underwent TAVR between 2016 and 2018, and who did not require a pacemaker before discharge. All of them were subjected to 30-day outpatient monitoring for the detection of high-grade conduction disorders (beyond 2 days after implantation).


Read also: Mortality and Paclitaxel Devices, Data Are Aligning.


During this period, outpatient monitoring detected high-grade conduction disorders in 10% of patients, at a median of 6 days (range 3 to 24 days) after TAVR. Patients who experienced high-grade block were more likely to have hypertension and complete right bundle branch block compared with those who did not experience it.

Sensitivity and specificity of complete right bundle branch block for the prediction of delayed high-grade conduction disorders after TAVR were 27% and 94%, respectively.

Original Title: Ambulatory Rhythm Monitoring to Detect Late High-Grade Atrioventricular Block Following Transcatheter Aortic Valve Replacement.

Reference: Karen Ream et al. J Am Coll Cardiol 2019;73:2538–47.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

Coronary artery disease progression after transcatheter aortic valve replacement: quantitative coronary angiography and Quantitative Flow Ratio analysis

The coexistence of coronary artery disease and severe aortic stenosis is common among patients undergoing transcatheter aortic valve replacement (TAVR). However, the impact of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...